Halozyme jumps on PEGPH20 update in pancreatic cancer
This article was originally published in Scrip
Executive Summary
San Diego-based Halozyme Therapeutics jumped 24.5% to $12.52 per share on 7 January based on Phase II data revealed during an analyst and investor update that showed efficacy for PEGPH20 in patients with metastatic pancreatic cancer whose tumors have high levels of hyaluronan (HA).
You may also be interested in...
CFO Joshua Smiley On Lilly’s Next Decade Of Growth
Lilly is planning for growth even beyond the loss of patent protection for Trulicity in 2027. In addition to internal R&D, Smiley said a third of new drugs will come from business development.
Legend Biotech CEO Ying Huang On Moving Fast In the BCMA CAR-T Race
Ying Huang was named CEO as his predecessor came under investigation in China and as partner Janssen was getting closer to seeking US FDA approval for its lead CAR-T therapy.
Finance Watch: Investors Remain Receptive To Biopharma, Health Care SPAC IPOs
Public Company Edition: 2020 started with two $200m-plus initial public offerings plus five health care-focused special purpose acquisition corporations IPOs. Also, a Pfizer initiative backs three public companies, Fate’s $432m offering led recent FOPOs and Biocon Biologics receives more investment.
Need a specific report? 1000+ reports available
Buy Reports